Inhibrx Biosciences — Third Quarter 2026 Earnings Summary

Inhibrx Biosciences reported a net loss of $38.7 million for the third quarter of 2026, driven by $26.0 million in research and development expenses and $7.8 million in general and administrative costs. The company recognized $2.0 million in revenue from a non-exclusive license agreement with Pfizer, while cash and cash equivalents increased to $199.5 million as of September 30, 2026. Clinical milestones include upcoming data presentations for ozekibart in Ewing sarcoma and the ongoing enrollment of ordastobart in head and neck squamous cell carcinoma. Additionally, the company is advancing commercial readiness activities for ozekibart in chondrosarcoma while preparing for a potential Biologics License Application.